

FOR IMMEDIATE RELEASE



September 17, 2013

AnGes MG, Inc.

**AnGes, Inc. Submits the Protocol for Small-scale Study of
Collategene[®] for IRB Review**

AnGes MG, Inc. (AnGes) announced today that its subsidiary, AnGes, Inc., (Maryland, United States [US]) submitted the protocol of Collategene[®]'s small-scale study for Institutional Review Board (IRB) review at the trial site (Dartmouth College, US). The small-scale study is a preliminary feasibility study of the global Phase III study of Collategene[®] for the treatment of critical limb ischemia.

As already announced by AnGes, the protocol of the small-scale study has been accepted by the US Food and Drug Administration (FDA) and completed the RAC review by the National Institute of Health (NIH). Upon completion of those procedures, AnGes submitted the protocol to receive IRB review of the trial site for the small-scale study.

IRB is a committee formed at an institution in which a clinical trial will take place. IRB comprehensively reviews the human rights and safety of participants. IRB is an independent committee that consists of specialists as well as non-specialists of medical science.

AnGes Group plans to start the small-scale study, as well as to complete necessary preparations prior to the initiation of the global Phase III study, with the aim of delivering the treatment to patients living with critical limb ischemia who currently have no treatment options available.

This event has no effects on business performance for the fiscal year 2013.

###

Disclaimer: This is a translation of the news release posted in Japanese. In case of any deviations between the two language versions, the original document in Japanese shall take precedence.

<p>AnGesMG, Inc. Corporate Communications TEL: +81-3-5730-2641, FAX: +81-3-5730-2635 http://www.anges-mg.com</p>
--